2,6-Difluoro-4-hydroxybenzonitrile | CAS:123843-57-2

We serve 2,6-Difluoro-4-hydroxybenzonitrile CAS:123843-57-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
2,6-Difluoro-4-hydroxybenzonitrile

Chemical Name:2,6-Difluoro-4-hydroxybenzonitrile
CAS.NO:123843-57-2
Synonyms:2,6-Difluoro-4-hydroxybenzonitrile
4-Cyano-3,5-difluorophenol
2,6-Difluoro-4-hydroxy benzonitrile
 
Physical and Chemical Properties:
Density 1.5±0.1 g/cm3
Boiling Point 279.8±40.0 °C at 760 mmHg
Melting Point 127 °C
Molecular Formula C7H3F2NO
Molecular Weight 155.102
Flash Point 123.0±27.3 °C
Vapour Pressure 0.0±0.6 mmHg at 25°C
Index of Refraction 1.530
 
Specification:
Appearance:White to off-white crystalline powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Organic synthesis.



Contact us for information like 2,6-Difluoro-4-hydroxybenzonitrile chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2,6-Difluoro-4-hydroxy benzonitrile physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-Cyano-3,5-difluorophenol Use and application,4-Cyano-3,5-difluorophenol technical grade,usp/ep/jp grade.


Related News: This followed a declaration Thursday by the World Health Organization that the coronavirus outbreak is a Public Health Emergency of International Concern.Potassium azeloyl diglycinate manufacturer This followed a declaration Thursday by the World Health Organization that the coronavirus outbreak is a Public Health Emergency of International Concern.9-(2-naphthalenyl)-3,6-Dibromo-9H-carbazole supplier Rigosertib, Onconova’s lead candidate, is a proprietary Phase 3 small molecule.cyclohexylamine vendor Mankind Pharmaceuticals on Monday said it has inked a licensing pact with Glenmark Pharmaceuticals to co-market diabetes drug Remogliflozin Etabonate in the country.Mankind Pharmaceuticals on Monday said it has inked a licensing pact with Glenmark Pharmaceuticals to co-market diabetes drug Remogliflozin Etabonate in the country.